Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients

Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients - Effectiveness and safety of TAF

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029099

Enrollment

650

Registered

2017-11-01

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis B or cirrhosis who received tenofovir alafenamide

Exclusion criteria

Exclusion criteria: insufficient of clinical data

Design outcomes

Primary

Measure	Time frame
Decline of HBsAg Seroclearance rate of HBsAg	—

Secondary

Measure	Time frame
Normalized rate of ALT Undetectable rate of HBV DNA and HBeAg Changes of serum creatinine, eGFR, serum phosphate, urinary protein, urinary NAG, urinary beta-2-microglobrin, bone density	—

Countries

Japan

Contacts

Public ContactTetsuya Hosaka

Toranomon branch Hospital Hepatology

hosa-p@toranomon.gr.jp044-877-5111

Outcome results